Search

Your search keyword '"Steg, Ph. Gabriel"' showing total 902 results

Search Constraints

Start Over You searched for: Author "Steg, Ph. Gabriel" Remove constraint Author: "Steg, Ph. Gabriel"
902 results on '"Steg, Ph. Gabriel"'

Search Results

104. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

107. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group

114. REDUCTION IN HEART FAILURE WITH ICOSAPENT ETHYL: INSIGHTS FROM REDUCE-IT HF

115. ICOSAPENT ETHYL REDUCES ISCHEMIC EVENTS IN PATIENTS WITH HIGH TRIGLYCERIDES AND LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS: REDUCE-IT HIGH TG/LOW HDL-C ANALYSES

116. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

117. Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

118. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

119. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis

120. Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial

121. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type

122. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial

123. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

124. One-year cardiovascular event rates in outpatients with atherothrombosis

125. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology

128. A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial

131. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

132. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study

137. The future of clinical trials in secondary prevention after acute coronary syndromes

139. HIV Infection and Long‐Term Residual Cardiovascular Risk After Acute Coronary Syndrome

148. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT

149. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

150. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

Catalog

Books, media, physical & digital resources